Chlorpheniramine is a first-generation anti-histamine that is used in the treatment of the following conditions:
- Perennial and seasonal Allergic rhinitis, urticaria, and pruritus
- Motion sickness
Chlorpheniramine Dose in Adults
Oral use in patients with Allergic symptoms, rhinitis, urticaria, and pruritus:
- Immediate-release formulations:
- 4 mg 4 - 6 hourly (Maximum dose should not exceed 24 mg/day)
- Extended-release tablets:
- 12 mg twice daily (The maximum dose should not exceed 24 mg/day)
Off-label use in Motion sickness:
- Immediate-release tablets:
- 4 - 12 mg administered 3 hours prior to the inciting stimulus for motion sickness
Chlorpheniramine Dose in Childrens
Oral use for allergic symptoms and rhinitis
- Immediate-release tablets and oral solutions:
- Children 2-6 years of age:
- 1 mg 4 - 6 hourly to a maximum daily dose of 6 mg/day
- Children 6 - 11 years of age:
- 2 mg 4-6 hourly to a maximum daily dose of 12 mg/day
- Children older than 12 years and Adolescents:
- 4 mg 4 - 6 hourly to a maximum daily dose of 24 mg/day
- Children 2-6 years of age:
- Extended-Release tablets
- Children older than 12 years and Adolescents:
- 12 mg twice daily to a maximum daily dose of 24 mg per day.
- Children older than 12 years and Adolescents:
Pregnancy Risk Factor B
- Its use in pregnancy has not been associated with birth defects and may be used in patients with rhinitis, urticaria, pruritis, and rash in pregnant women (Preferably use second-generation antihistamines)
- To treat intrahepatic cholesterolemia of pregnancy, antihistamines should be avoided.
Use during breastfeeding:
- It can be excreted in breastmilk, and can cause drowsiness or irritability in infants breastfed.
- Breastfed infants need to be watched for irritability or drowsiness.
- Furthermore, the newer generation antihistamines should be preferred over the first generation antihistamines.
- Antihistamines can also reduce serum prolactin levels and milk production.
Chlorpheniramine Dose in Kidney Disease:
The manufacturer has not recommended any dose adjustment in patients with renal disease.
Chlorpheniramine Dose in Liver Disease:
- The manufacturer has not recommended any dose adjustment in patients with liver disease.
- However, since, it is metabolized by the liver, it should be used with caution.
Common Side Effects of Chlorpheniramine:
- Central nervous system:
- Drowsiness (slight to moderate)
- Respiratory:
- Thickening of bronchial secretions
Less Common Side Effects of Chlorpheniramine:
- Central nervous system:
- Dizziness
- Excitability
- Fatigue
- Headache
- Nervousness
- Endocrine & metabolic:
- Weight gain
- Gastrointestinal:
- Abdominal pain
- Diarrhea
- Increased appetite
- Nausea
- Xerostomia
- Genitourinary:
- Urinary retention
- Neuromuscular & skeletal:
- Arthralgia
- Weakness
- Ophthalmic:
- Diplopia
- Renal:
- Polyuria
- Respiratory:
- Pharyngitis
Contraindication to Chlorpheniramine:
- Allergy to chlorpheniramine-maleate or any component of the formulation
- Narrow-angle glaucoma
- Bloat at the Bladder Outlet
- Prostate hypertrophy symptoms
- Acute asthmatic attacks
- Peptic ulcer surgery
- Pyloroduodenal obstruction
- Due to the possibility of sudden infant death syndrome, avoid premature or term newborns.
- Avoid using children's sleeping pills.
Warnings and Precautions
- CNS depression:
- It can cause CNS depression and sedation that could lead to mental or physical impairments. It should be used with caution by patients who are required to maintain mental alertness for tasks.
- Cardiovascular disease
- Patients suffering from cardiovascular disease such as hypertension or ischemic heart disease, should not take the drug.
- Increased intraocular pressure
- May precipitate glaucoma. Patients with elevated intraocular pressure should not use it.
- Prostatic hyperplasia and urinary obstruction:
- It can cause urinary retention in the elderly.
- Respiratory disease
- When using the medication, those with asthma or chronic obstructive pulmonary disorders (COPD) should exercise caution.
- Thyroid dysfunction:
- Patients with thyroid dysfunction should use it with caution.
Chlorpheniramine: Drug Interaction
Note: Drug Interaction Categories:
- Risk Factor C: Monitor When Using Combination
- Risk Factor D: Consider Treatment Modification
- Risk Factor X: Avoid Concomitant Use
Risk Factor C (Monitor therapy). |
|
| Acetylcholinesterase inhibitors | Anticholinergic Agents may have a decreased therapeutic effect. Anticholinergic Agents can decrease the therapeutic effects of Acetylcholinesterase inhibitors. |
| Ajmaline | High risk of Inhibitors increasing serum concentrations of CYP2D6 Substrates |
| Alcohol (Ethyl) | CNS Depressants can increase the CNS depressant effects of Alcohol (Ethyl). |
| Alizapride | CNS Depressants may increase the CNS depressant effects. |
| Amantadine | Anticholinergic Agents may have an enhanced anticholinergic effect. |
| Amezinium | Amezinium may have a stronger stimulatory effect if it is combined with antihistamines. |
| Amphetamines | May lessen antihistamines' sedative effects. |
| Anticholinergic Agents | Other Anticholinergic Agents may have an adverse/toxic effect. |
| Betahistine | Betahistine's therapeutic effects may be diminished by antihistamines. |
| Botulinum Toxin-Containing Products | Anticholinergic Agents may have an enhanced anticholinergic effect. |
| Brexanolone | CNS Depressants can increase the CNS depressant effects of Brexanolone. |
| Brimonidine (Topical) | CNS Depressants may increase the CNS depressant effects. |
| Bromopride | CNS Depressants may increase the CNS depressant effects. |
| Cannabidiol | CNS Depressants may increase the CNS depressant effects. |
| Cannabis | CNS Depressants may increase the CNS depressant effects. |
| Chloral Betaine | Anticholinergic drugs could be harmful or poisonous. |
| Chlorphenesin Carbamate | CNS Depressants may have an adverse/toxic effect that can be exacerbated by them. |
| CloBAZam | High risk of Inhibitors increasing serum concentrations of CYP2D6 Substrates |
| CNS Depressants | Can increase the toxic/adverse effects of CNS Depressants. |
| Cobicistat | High risk of Inhibitors increasing serum concentrations of CYP2D6 Substrates |
| Moderate CYP2D6 inhibitors | Might decrease metabolism of CYP2D6 substrates (High Risk with Inhibitors). |
| Darunavir | High risk of Inhibitors increasing serum concentrations of CYP2D6 Substrates |
| Dimethindene (Topical). | CNS Depressants may increase the CNS depressant effects. |
| Doxylamine | If taken alongside other CNS Depressants, CNS Depressants may have a stronger CNS depressing impact. Management: The producer of the pregnancy-safe drug Diclegis (doxylamine/pyridoxine) particularly advises against combining it with other CNS depressants. |
| Dronabinol | CNS Depressants may intensify the effects of CNS Depressants. |
| Esketamine | CNS Depressants may intensify the effects of CNS Depressants. |
| Fosphenytoin-Phenytoin | Chlorpheniramine may increase the serum concentration of Fosphenytoin-Phenytoin. |
| Gastrointestinal Agents (Prokinetic) | Anticholinergic Agents can reduce the therapeutic effects of Gastrointestinal Agents (Prokinetic). |
| Glucagon | Anticholinergic agents may increase the toxic/adverse effects of Glucagon. Particularly, there may be an increase in the likelihood of gastrointestinal adverse reactions. |
| HydrOXYzine | CNS Depressants may increase the CNS depressant effects. |
| Imatinib | High risk of Inhibitors increasing serum concentrations of CYP2D6 Substrates |
| Itopride | Itopride's therapeutic effects may be diminished by anticholinergic agents. |
| Kava Kava | CNS Depressants may have an adverse/toxic effect that can be exacerbated by them. |
| Lofexidine | CNS Depressants may have a greater depressant effect on the brain. Management: Separate drug interaction monographs are available for drugs listed as an exception to this monograph. |
| Lumefantrine | High risk of Inhibitors increasing serum concentrations of CYP2D6 Substrates |
| Magnesium Sulfate | CNS Depressants may increase the CNS depressant effects. |
| MetyroSINE | MetyroSINE may have a sedative effect that can be enhanced by CNS depressants. |
| Mianserin | Anticholinergic Agents may have an enhanced anticholinergic effect. |
| Minocycline | CNS Depressants may increase the CNS depressant effects. |
| Mirabegron | Anticholinergic agents may increase the toxic/adverse effects of Mirabegron. |
| Mirtazapine | CNS Depressants can increase the CNS depressant effects of Mirtazapine. |
| Nabilone | CNS Depressants may increase the CNS depressant effects. |
| Nitroglycerin | Anticholinergic medications may reduce Nitroglycerin's absorption. Anticholinergic drugs may slow down the sublingual nitroglycerin tablet's ability to dissolve, which could hinder or delay nitroglycerin absorption. |
| Panobinostat | High risk of Inhibitors increasing serum concentrations of CYP2D6 Substrates |
| Peginterferon Alfa-2b | Inhibitors carry a high danger. may reduce the levels of CYP2D6 substrates in serum. Serum levels of CYP2D6 Substrates may rise after administration of peginterferon Alf-2b. |
| Perhexiline | Perhexiline may be increased by CYP2D6 Substrates. Perhexiline can increase serum concentrations of CYP2D6 substrates (High Risk with Inhibitors). |
| Piribedil | CNS Depressants could increase the CNS depressant effects of Piribedil. |
| Pitolisant | Antihistamines can reduce the therapeutic effects of Pitolisant. |
| Pramipexole | Pramipexole may have a greater sedative effect if it is combined with CNS depressants. |
| QuiNINE | High risk of Inhibitors increasing serum concentrations of CYP2D6 Substrates |
| Ramosetron | Ramosetron's constipating effects may be enhanced by anticholinergic agents. |
| ROPINIRole | CNS Depressants can increase the sedative effects of ROPINIRole. |
| Rotigotine | CNS Depressants can increase the sedative effects of Rotigotine. |
| Rufinamide | CNS Depressants may have an adverse/toxic effect that can be exacerbated by this. Particularly, dizziness and sleepiness may be increased. |
| Selective Serotonin Reuptake inhibitors | CNS Depressants can increase the toxic/adverse effects of Selective Serotonin Resuptake Inhibitors. Particularly, psychomotor impairment could be increased. |
| Tetrahydrocannabinol | CNS Depressants may increase the CNS depressant effects. |
| Tetrahydrocannabinol, and Cannabidiol | CNS Depressants may increase the CNS depressant effects. |
| Thiazide and Thiazide - Like Diuretics | Anticholinergic Agents can increase serum Thiazide or Thiazide-Like Diuretics. |
| Topiramate | Topiramate's toxic/adverse effects may be exacerbated by anticholinergic agents. |
| Trimeprazine | CNS Depressants may intensify the effects of CNS Depressants. |
Risk Factor D (Consider therapy modifications) |
|
| Abiraterone Acetate | High risk of Inhibitors causing an increase in serum concentrations of CYP2D6 substrates. When possible, avoid concurrent use of abiraterone and CYP2D6 Substrates with a narrow therapeutic index. If concurrent use cannot be avoided, closely monitor patients for signs and symptoms of toxic effects. |
| Asunaprevir | High risk of Inhibitors increasing serum concentrations of CYP2D6 Substrates |
| BenzylpenicilloylPolylysine | Antihistamines may reduce BenzylpenicilloylPolylysine's ability to diagnose. Management: Delay testing until systemic antihistaminic effects have subsided and discontinue systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing. A histamine skin test can be used to check for lingering antihistaminic effects. |
| Blonanserin | CNS Depressants can increase the CNS depressant effects of Blonanserin. |
| Buprenorphine | CNS Depressants can increase the CNS depressant effects of buprenorphine. Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Buprenorphine patches (Butrans) should be initiated at 5 mg/hr for adults when taken with other CNS depression drugs. |
| Chlormethiazole | CNS Depressants may increase the CNS depressant effects. Monitoring: Look out for signs of CNS depression. If a combination of chlormethiazole and other drugs is required, a reduced dose should be used. |
| Strong CYP2D6 inhibitors | Might decrease metabolism of CYP2D6 substrates (High Risk with Inhibitors). |
| Dacomitinib | High risk of Inhibitors causing an increase in serum concentrations of CYP2D6 substrates. Management: Do not use dacomitinib concurrently with CYP2D6 Substrates that have a narrow therapeutic Index. |
| Droperidol | CNS Depressants may increase the CNS depressant effects. Management: Droperidol and other CNS agents, such as opioids, may be reduced or used in combination with droperidol. Separate drug interaction monographs provide more detail on exceptions to this monograph. |
| Flunitrazepam | CNS Depressants can increase the CNS depressant effects of Flunitrazepam. |
| Hyaluronidase | Antihistamines may lessen the therapeutic effects of hyaluronidase. Treatment: Patients taking antihistamines, especially at larger doses, may not respond clinically to hyaluronidase at conventional doses. Hyaluronidase dosages may need to be increased. |
| HYDROcodone | CNS Depressants can increase the CNS depressant effects of HYDROcodone. When possible, avoid concomitant use with hydrocodone and other CNS depressants. Combining these agents is not recommended unless there are other options. Limit the amount and duration of each drug when combined. |
| Methotrimeprazine | Methotrimeprazine may have a higher CNS depressant activity than CNS Depressants. Methotrimeprazine can increase the CNS depressant effects of CNS Depressants. Management: Lower the adult dose of CNS Depressants by 50% and start concomitant methotrimeprazine treatment. After clinically proven efficacy of methotrimeprazine, further CNS depressant dose adjustments should only be made. |
| Opioid Agonists | CNS Depressants can increase the CNS depressant effects of Opioid Aggonists. Management: When possible, avoid concomitant use opioid agonists and other CNS depressants. Combining these agents is not recommended unless there are other options. Limit the amount and duration of each drug when combined. |
| OxyCODONE | CNS Depressants can increase OxyCODONE's CNS depressant effects. When possible, avoid the simultaneous use of oxycodone and other CNS depressants. Combining these agents is not recommended unless there are other options. Limit the amount and duration of each drug when combined. |
| Perampanel | CNS Depressants may have a greater CNS depressant effect. Perampanel and any other CNS depressant drug should be used in combination. Patients who take perampanel together with any other drug should not engage in complex or high-risk activities until they have had experience with the combination. |
| Pramlintide | Anticholinergic Agents may have an enhanced anticholinergic effect. These effects are only for the GI tract. |
| Secretin | Secretin's therapeutic effects may be diminished by anticholinergic agents. Concomitant use: Secretin and anticholinergic agents should be avoided. Stop using anticholinergic drugs for at least five half-lives before administering secretin. |
| Sodium Oxybate | CNS Depressants may have a greater depressant effect if taken in combination. Management: Look for alternatives to the combination use. If you must combine use, reduce the doses of any one or more drugs. It is not recommended to combine sodium oxybate and alcohol, or any sedative hypnotics. |
| Suvorexant | CNS Depressants can increase the CNS depressant effects of Suvorexant. Management: Suvorexant or any other CNS depressionant can be reduced in doses. Suvorexant should not be taken with alcohol. It is also not recommended to take suvorexant along with any other drugs for insomnia. |
| Tapentadol | CNS Depressants may increase the CNS depressant effects. Tapentadol, benzodiazepines and other CNS depressants should be avoided when possible. Combining these agents is not recommended unless there are other options. Limit the amount and duration of each drug when combined. |
| Thioridazine | Thioridazine may have an arrhythmogenic effect that is enhanced by Chlorpheniramine. The serum concentration of Chlorpheniramine may be increased by Thioridazine. Management: If possible, avoid this combination. Monitor closely for arrhythmia and general toxicity of chlorpheniramine if you use it. |
| Zolpidem | CNS Depressants can increase the CNS depressant effects of Zolpidem. Management: For men who also take CNS depressants, reduce the adult Intermezzo brand sublingual Zolpidem dose to 1.75mg. For women, no dose adjustment is advised. Avoid using CNS depressants at night; do not use alcohol. |
Risk Factor X (Avoid Combination) |
|
| Aclidinium | Anticholinergic Agents may have an enhanced anticholinergic effect. |
| Azelastine (Nasal | CNS Depressants could increase the CNS depressant effects of Azelastine. |
| Bromperidol | CNS Depressants may increase the CNS depressant effects. |
| Cimetropium | Cimetropium may have an anticholinergic effect that can be enhanced by the use of anticholinergic agents. |
| Eluxadoline | Eluxadoline may cause constipation by using anticholinergic agents. |
| Glycopyrrolate (Oral Inhalation) | Anticholinergic agents may increase the anticholinergic effects of Glycopyrrolate (Oral inhalation). |
| Glycopyrronium (Topical) | Anticholinergic Agents may have an enhanced anticholinergic effect. |
| Oral Inhalation with Ipratropium | Anticholinergic Agents may have an enhanced anticholinergic effect. |
| Levosulpiride | Anticholinergic Agents can reduce the therapeutic effects of Levosulpiride. |
| Orphenadrine | Orphenadrine may be more effective against CNS depression than other drugs. |
| Oxatomide | Anticholinergic Agents may have an enhanced anticholinergic effect. |
| Oxomemazine | CNS Depressants may increase the CNS depressant effects. |
| Paraldehyde | Paraldehyde may be enhanced by CNS depressants. |
| Potassium Chloride | Potassium Chloride may have an ulcerogenic effect that can be exacerbated by anticholinergic agents. Treatment: Patients taking drugs that have significant anticholinergic effects should not consume any oral dose form of potassium chloride. |
| Potassium Citrate | If potassium citrate is administered with anticholinergic drugs, it can increase the risk of ulcers. |
| Revefenacin | Revefenacin may be enhanced by anticholinergic agents. |
| Thalidomide | CNS Depressants can increase Thalidomide's CNS depressant effects. |
| Tiotropium | Anticholinergic agents may increase the anticholinergic effects of Tiotropium. |
| Umeclidinium | Anticholinergic Agents may have an enhanced anticholinergic effect. |
Monitoring Parameters:
None required. Monitor symptoms control.
How to Administer Chlorpheniramine?
- It may be administered with food or water.
- When used for motion sickness, it should be administered 3 hours before the stimulus.
- It should not be crushed or chewed and swallowed as a whole.
Mechanism of action of Chlorpheniramine:
It is an anti-allergic medication that works by competing with histamine receptors located in the gastrointestinal tract, blood vessels and respiratory tract.
It is 33%Protein-boundAndMetabolizedby the liver via CYP450 enzymes. It is aHalf-lifeThe time taken to reach the destination can vary from 6 to 24 hours.peak plasma concentrationIt takes between 1 and 6 hours.
It isexcretedPrimarily via urine
International Brands of Chlorpheniramine:
- Aller-Chlor
- Allergy Relief
- Allergy
- Allergy-Time
- Chlor-Trimeton Allergy
- Chlor-Trimeton
- Ed Chlorped Jr
- Ed ChlorPed
- Ed-Chlortan
- Pharbechlor
- Acira
- Ahiston
- Alergidryl
- Alergitrat
- Aller
- Allerfin
- Allergex
- Allermin
- Allermine
- Alleryl
- Analer
- Analerg
- Anallerge
- Antamin
- Bregamin
- Cadistin
- Chlofen
- Chloramine
- Chlorohistal
- Chlorohistan
- Chlorohistol
- Chlorpheniramine DHA
- Chlorpheno
- Chlorphenon
- Chlorpyrimine
- Chlortrimeton
- Cipium
- Clorfam
- Cloro Trimeton
- Cloro-Trimeton
- Cloroalergan
- Cohistan
- Com-Trimeton
- Derimeton
- Histafen
- Histal
- Histalex
- Histan
- Histant
- Histat
- Histatapp
- Histavil
- Histon
- Histop
- Horamine
- Isticol Jarabe
- Lergisina
- Lorecare
- Nipolen
- Niramine
- Orphen
- Peniramin
- Pheneton 4
- Pheniram
- Piriton
- Prodel
- Sensitamine
- Sprinsol
- Trimeton
- Valemine
Chlorpheniramine Brands in Pakistan:
|
Chlorpheniramine (Maleate) [Inj 10 mg/ml] |
|
| CHLOR | FRIENDS PHARMA (PVT) LTD |
| CHLORPHENIRAMINE | ORIENT LABORATORIES |
| CHLORPHENIRAMINE | GEOFMAN PHARMACEUTICALS |
| CHLORPHENIRAMINE | PLIVA PAKISTAN (PVT) LIMITED |
| HAMZIVIL | ELITE PHARMA |
|
Chlorpheniramine(Maleate) [Syrup 2 mg/5ml] |
|
| ALLERGEX | NABIQASIM INDUSTRIES (PVT) LTD. |
| ALLERGON | MEDICRAFT PHARMACEUTICALS (PVT) LTD. |
| ALLERMINE | KRKA-PAK PHARMACEUTICAL & CHEMICAL WORKS |
| ALLERMINE | KRKA-PAK PHARMACEUTICAL & CHEMICAL WORKS |
| ALLERPHENE | P.D.H. PHARMACEUTICALS (PVT) LTD. |
| CEPIAM | ARDIN PHARMACEUTICALS |
| CHLORPHENIRAMINE | LISKO PAKISTAN (PVT) LTD |
| CHLORPHENIRAMINE | ORTA LABS. (PVT) LTD. |
| CHLORPHENIRAMINE | MIAN BROTHERS LABORATORIES (PVT) LTD. |
| CHLORPHENIRAMINE | KARACHI PHARMACEUTICAL LABORATORY |
| CHLORPHENIRAMINE | EROS PHARMACEUTICALS |
| CHLORPHENIRAMINE MALEATE | JAWA PHARMACEUTICALS(PVT) LTD. |
| COLEN | ALLIANCE PHARMACEUTICALS (PVT) LTD. |
| FENRAM | ALBRO PHARMA |
| HISTAGIC | LISKO PAKISTAN (PVT) LTD |
| HISTALON | POLYFINE CHEMPHARMA (PVT) LTD. |
| LOLRPHINE | NEUTRO PHARMA (PVT) LTD. |
| NIRMINE | DAVIS PHARMACEUTICAL LABORATORIES |
| PHEMIN | MARVI LABORATORIES |
| PHENAMINE | MUNAWAR PHARMA (PVT) LTD. |
| PHENERMIN | SEMOS PHARMACEUTICALS (PVT) LTD. |
| REPHENIRAMINE | SYNTEX PHARMACEUTICALS |
| RESMIN | RASCO PHARMA |
| RHINOL | IRZA PHARMA (PVT) LTD. |
| STAITON | STANDARD DRUG CO. |
| UNIHIST | UNISON CHEMICAL WORKS |
|
Chlorpheniramin (Maleate) [Syrup 2.5 mg/5ml] |
|
| SYPRITON | SAYYED PHARMACEUTICALS |
|
Chlorpheniramine (Maleate) [Tabs 4 mg] |
|
| ALLERMINE | KRKA-PAK PHARMACEUTICAL & CHEMICAL WORKS |
| ALLERPHENE | P.D.H. PHARMACEUTICALS (PVT) LTD. |
| ALLERVIL | INDUS PHARMA (PVT) LTD. |
| ALPHEM | ALSON PHARMACEUTICALS |
| APITON | EURO PHARMA INTERNATIONAL |
| BARITON | BATALA PHARMACEUTICALS. |
| CHLOFAMIN | ALFALAH PHARMA (PVT) LTD. |
| CHLOROPHENIRAMINE MALEATE | IRZA PHARMA (PVT) LTD. |
| CHLORPHENIRAMINE | KARACHI PHARMACEUTICAL LABORATORY |
| CHLORPHENIRAMINE | PHARMACARE LABORATORIES (PVT) LTD. |
| CHLORPHENIRAMINE | IDEAL PHARMACEUTICAL INDUSTRIES |
| CHLORPHENIRAMINE | MIAN BROTHERS LABORATORIES (PVT) LTD. |
| CHLORPHENIRAMINE | MUNAWAR PHARMA (PVT) LTD. |
| CHLORPHENIRAMINE | SEMOS PHARMACEUTICALS (PVT) LTD. |
| CHLORPHENIRAMINE | UNEXO LABS (PVT) LTD. |
| CHLORPHENIRAMINE | XENON PHARMACEUTICALS (PVT) LTD. |
| CHLORPHENIRAMINE | LISKO PAKISTAN (PVT) LTD |
| CHLORPHENIRAMINE | EROS PHARMACEUTICALS |
| CHLORPHENIRAMINE MALEATE | ARDIN PHARMACEUTICALS |
| CHLORPHENIRAMINE MALEATE | JAWA PHARMACEUTICALS(PVT) LTD. |
| CHLORPHENIRAMINE MALEATE | ETHICAL LABORATORIES (PVT) LTD. |
| DEEMINE | DELUX CHEMICAL INDUSTRIES |
| DHLORAMINE | KOHS PHARMACEUTICALS |
| FENAMINE | FLOW PHARMACEUTICALS (PVT) LTD. |
| FENRAM | ALBRO PHARMA |
| HARITON | HEALERS LABORATORIES |
| HISTAGIC | LISKO PAKISTAN (PVT) LTD |
| HISTAMOL | EPLA LABORATORIES (PVT) LTD. |
| HISTOM | KARACHI CHEMICAL INDUSTRIES |
| PHEMIN | MARVI LABORATORIES |
| PHENERMIN | SEMOS PHARMACEUTICALS (PVT) LTD. |
| PHENIR | VALOR PHARMACEUTICALS |
| PIRITON | GLAXOSMITHKLINE |
| REPHENIRAMINE | SYNTEX PHARMACEUTICALS |
| RESMIN | RASCO PHARMA |
| STAITON | STANDARD DRUG CO. |
|
Chlorpheniramine (Maleate) [Tabs 10 mg] |
|
| CHLORPHENIRAMINE MALEATE | SHIFA LABORATORIES.(PVT) LTD. |
